# Study of the Safety, Tolerability, and PK of PRA-027 Administered to Women of Nonchildbearing Potential

> **NCT00427544** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer**

## Conditions studied

- Fibroid

## Interventions

- **DRUG:** PRA-027

## Key facts

- **NCT ID:** NCT00427544
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** —
- **Final completion:** 2007-08
- **Target enrollment:** — (—)
- **Last updated:** 2007-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00427544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00427544, "Study of the Safety, Tolerability, and PK of PRA-027 Administered to Women of Nonchildbearing Potential". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00427544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*